{"entity": "publication", "iuid": "7a090d7f9a4446ae84c17bcb262f839c", "timestamp": "2026-09-28T11:19:33.289Z", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/7a090d7f9a4446ae84c17bcb262f839c.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/7a090d7f9a4446ae84c17bcb262f839c"}}, "title": "Convergence of EGFR glioblastoma mutations: evolution and allostery rationalizing targeted therapy.", "authors": [{"family": "Orellana", "given": "Laura", "initials": "L", "orcid": "0000-0003-1927-555X", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/4a8c40da814843c6ac1bda02a0f32804.json"}}], "type": "journal article", "published": "2019-07-04", "journal": {"title": "Mol Cell Oncol", "issn": "2372-3556", "volume": "6", "issue": "5", "pages": "e1630798", "issn-l": null}, "abstract": "EGFR mutations display striking organ-site asymmetry and heterogeneity. We have shown that structurally diverse extracellular mutations, typical of glioblastomas, converge to a similar intermediate conformation, which can be synergistically targeted extra- and intracelullarly by antibody mAb806 and type-II kinase inhibitors. Our findings reveal convergence behind heterogeneity, paving the way for allostery-based co-targeting.", "doi": "10.1080/23723556.2019.1630798", "pmid": "31528699", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC6736128"}, {"db": "pii", "key": "1630798"}], "notes": [], "created": "2026-09-23T12:49:27.494Z", "modified": "2026-09-23T12:49:27.527Z"}